{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T05:47:08Z","timestamp":1771048028667,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T00:00:00Z","timestamp":1579910400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T00:00:00Z","timestamp":1579910400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s00408-020-00331-8","type":"journal-article","created":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T17:02:16Z","timestamp":1579971736000},"page":"299-306","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Chitotriosidase Activity in Plasma and COPD Exacerbations"],"prefix":"10.1007","volume":"198","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9643-1934","authenticated-orcid":false,"given":"Matevz","family":"Harlander","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Lestan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matjaz","family":"Turel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,1,25]]},"reference":[{"key":"331_CR1","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1172\/JCI36130","volume":"118","author":"PJ Barnes","year":"2008","unstructured":"Barnes PJ (2008) The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 118:3546\u20133556","journal-title":"J Clin Invest"},{"key":"331_CR2","doi-asserted-by":"publisher","first-page":"e37483","DOI":"10.1371\/journal.pone.0037483","volume":"7","author":"A Agust\u00ed","year":"2012","unstructured":"Agust\u00ed A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, et al (2012) Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS ONE 7:e37483","journal-title":"PLoS ONE"},{"key":"331_CR3","first-page":"698","volume":"20","author":"G Paone","year":"2016","unstructured":"Paone G, Leone V, Conti V, De Marchis L, Ialleni E, Graziani C et al (2016) Blood and sputum biomarkers in COPD and asthma: a review. Eur Rev Med Pharmacol Sci 20:698\u2013708","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"331_CR4","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1007\/s00018-006-6269-2","volume":"63","author":"L Malaguarnera","year":"2006","unstructured":"Malaguarnera L (2006) Chitotriosidase: the yin and yang. Cell Mol Life Sci 63:3018\u20133029","journal-title":"Cell Mol Life Sci"},{"key":"331_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1875044301205010001","volume":"5","author":"M Kanneganti","year":"2012","unstructured":"Kanneganti M, Kamba A, Mizoguchi E (2012) Role of chitotriosidase (chitinase 1) under normal and disease conditions. J Epithel Biol Pharmacol 5:1\u20139","journal-title":"J Epithel Biol Pharmacol"},{"key":"331_CR6","doi-asserted-by":"publisher","first-page":"638","DOI":"10.2353\/ajpath.2010.090455","volume":"176","author":"S L\u00e9tuv\u00e9","year":"2010","unstructured":"L\u00e9tuv\u00e9 S, Kozhich A, Humbles A, Brewah Y, Dombret M-C, Grandsaigne M et al (2010) Lung chitinolytic activity and chitotriosidase are elevated in chronic obstructive pulmonary disease and contribute to lung inflammation. Am J Pathol 176:638\u2013649","journal-title":"Am J Pathol"},{"key":"331_CR7","doi-asserted-by":"publisher","first-page":"5167","DOI":"10.4049\/jimmunol.181.7.5167","volume":"181","author":"S L\u00e9tuv\u00e9","year":"2008","unstructured":"L\u00e9tuv\u00e9 S, Kozhich A, Arouche N, Grandsaigne M, Reed J, Dombret M-C et al (2008) YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J Immunol 181:5167\u20135173","journal-title":"J Immunol"},{"key":"331_CR8","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.2147\/COPD.S184097","volume":"14","author":"S Majewski","year":"2019","unstructured":"Majewski S, Tworek D, Szewczyk K, Kisza\u0142kiewicz J, Kurmanowska Z, Brzezia\u0144ska-Lasota E et al (2019) Overexpression of chitotriosidase and YKL-40 in peripheral blood and sputum of healthy smokers and patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 14:1611\u20131631","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"331_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1164\/rccm.201504-0760OC","volume":"193","author":"AJ James","year":"2016","unstructured":"James AJ, Reinius LE, Verhoek M, Gomes A, Kupczyk M, Hammar U et al (2016) Increased YKL-40 and chitotriosidase in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 193:131\u2013142","journal-title":"Am J Respir Crit Care Med"},{"key":"331_CR10","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1165\/2009-0122R","volume":"41","author":"E Agapov","year":"2009","unstructured":"Agapov E, Battaile JT, Tidwell R, Hachem R, Patterson GA, Pierce RA et al (2009) Macrophage chitinase 1 stratifies chronic obstructive lung disease. Am J Respir Cell Mol Biol 41:379\u2013384","journal-title":"Am J Respir Cell Mol Biol"},{"key":"331_CR11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1620\/tjem.229.163","volume":"229","author":"A Gumus","year":"2013","unstructured":"Gumus A, Kayhan S, Cinarka H, Kirbas A, Bulmus N, Yavuz A et al (2013) High serum YKL-40 level in patients with COPD is related to hypoxemia and disease severity. Tohoku J Exp Med 229:163\u2013170","journal-title":"Tohoku J Exp Med"},{"key":"331_CR12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2466-13-77","volume":"13","author":"DB Holmgaard","year":"2013","unstructured":"Holmgaard DB, Mygind LH, Titlestad IL, Madsen H, Pedersen SS, Johansen JS et al (2013) Plasma YKL-40 and all-cause mortality in patients with chronic obstructive pulmonary disease. BMC Pulm Med 13:77","journal-title":"BMC Pulm Med"},{"key":"331_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12931-016-0338-3","volume":"17","author":"T Lai","year":"2016","unstructured":"Lai T, Wu D, Chen M, Cao C, Jing Z, Huang L et al (2016) YKL-40 expression in chronic obstructive pulmonary disease: relation to acute exacerbations and airway remodeling. Respir Res 17:31","journal-title":"Respir Res"},{"key":"331_CR14","doi-asserted-by":"publisher","first-page":"1700214","DOI":"10.1183\/13993003.00214-2017","volume":"49","author":"CF Vogelmeier","year":"2017","unstructured":"Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J et al (2017) Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Eur Respir J 49:1700214","journal-title":"Eur Respir J"},{"key":"331_CR15","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1093\/gerona\/glt022","volume":"68","author":"R Ramanathan","year":"2013","unstructured":"Ramanathan R, Kohli A, Ingaramo MC, Jain A, Leng SX, Punjabi NM et al (2013) Serum chitotriosidase, a putative marker of chronically activated macrophages, increases with normal aging. J Gerontol A 68:1303\u20131309","journal-title":"J Gerontol A"},{"key":"331_CR16","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1183\/09031936.00092506","volume":"29","author":"WR Perera","year":"2007","unstructured":"Perera WR, Hurst JR, Wilkinson TMA, Sapsford RJ, M\u00fcllerova H, Donaldson GC et al (2007) Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J 29:527\u2013534","journal-title":"Eur Respir J"},{"issue":"944\u2013950","key":"331_CR17","first-page":"e3","volume":"122","author":"MA Seibold","year":"2008","unstructured":"Seibold MA, Donnelly S, Solon M, Innes A, Woodruff PG, Boot RG et al (2008) Chitotriosidase is the primary active chitinase in the human lung and is modulated by genotype and smoking habit. J Allergy Clin Immunol 122(944\u2013950):e3","journal-title":"J Allergy Clin Immunol"},{"key":"331_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/cea.12032","volume":"43","author":"ML Gavala","year":"2013","unstructured":"Gavala ML, Kelly EAB, Esnault S, Kukreja S, Evans MD, Bertics PJ et al (2013) Segmental allergen challenge enhances chitinase activity and levels of CCL18 in mild atopic asthma. Clin Exp Allergy 43:187\u2013197","journal-title":"Clin Exp Allergy"},{"key":"331_CR19","first-page":"501","volume":"22","author":"JH Lee","year":"2012","unstructured":"Lee JH, Park KH, Park JW, Hong CS (2012) YKL-40 in induced sputum after allergen bronchial provocation in atopic asthma. J Investig Allergol Clin Immunol 22:501\u2013507","journal-title":"J Investig Allergol Clin Immunol"},{"key":"331_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1465-9921-9-47","volume":"9","author":"T-L Hackett","year":"2008","unstructured":"Hackett T-L, Holloway R, Holgate ST, Warner JA (2008) Dynamics of pro-inflammatory and anti-inflammatory cytokine release during acute inflammation in chronic obstructive pulmonary disease: an ex vivo study. Respir Res 9:47","journal-title":"Respir Res"},{"key":"331_CR21","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1515\/CCLM.2005.088","volume":"43","author":"M Di Rosa","year":"2005","unstructured":"Di Rosa M, Musumeci M, Scuto A, Musumeci S, Malaguarnera L (2005) Effect of interferon-gamma, interleukin-10, lipopolysaccharide and tumor necrosis factor-alpha on chitotriosidase synthesis in human macrophages. Clin Chem Lab Med 43:499\u2013502","journal-title":"Clin Chem Lab Med"},{"key":"331_CR22","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S0140-6736(16)31354-X","volume":"388","author":"D Singh","year":"2016","unstructured":"Singh D, Papi A, Corradi M, Pavli\u0161ov\u00e1 I, Montagna I, Francisco C et al (2016) Single inhaler triple therapy versus inhaled corticosteroid plus long-acting \u03b22-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet 388:963\u2013973","journal-title":"Lancet"},{"key":"331_CR23","first-page":"837","volume":"79","author":"A Maver","year":"2010","unstructured":"Maver A, Medica I, Salobir B, Ter\u010delj-Zorman M, Peterlin B (2010) The role of chitotriosidase duplication gene polymorphism in the susceptibility to sarcoidosis. Zdr Vestn 79:837\u2013842","journal-title":"Zdr Vestn"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-020-00331-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00408-020-00331-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-020-00331-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T00:08:05Z","timestamp":1611446885000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00408-020-00331-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,25]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["331"],"URL":"https:\/\/doi.org\/10.1007\/s00408-020-00331-8","relation":{},"ISSN":["0341-2040","1432-1750"],"issn-type":[{"value":"0341-2040","type":"print"},{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,25]]},"assertion":[{"value":"28 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"M. Harlander reports personal fees from AstraZeneca, Berlin-Chemie Menarini, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis and Teva outside the submitted work. D. Lestan reports personal fees from Boehringer Ingelheim and Roche outside the submitted work. M. Turel reports personal fees from AstraZeneca, Berlin-Chemie Menarini, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis and Teva outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}